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Introduction
Hormonal pregnancy tests have been used for the early diagnosis of
pregnancy or amenorrhea of short duration since the late 1940's.

They

are

considered simple, inexpensive, accurate and, until recently, safe diagnostic
agents that could be given up to several weeks into pregnancy.

They contain

naturally occurring or synthetic progesterones with estrogens.

Their mechanism

of action is based on progesterone induced withdrawal bleeding in the estrogen
primed (proliferative phase) endometrium.

That is, orally or parentally

administered progesterone v/ith estrogen is given over a two to three day

period then abruptly discontinued.

If the woman is not pregnant the pro-

gesterone stimulated endometrium will be sloughed
ever, if she ;s pregnant the endometrium will be

~nd

bleeding induced.

~3intained

by

How-

progesterone

output from her own corpus luteum and/or the developing placenta.
Hormonal pregnancy tests were initially developed from progesterone
and estrogen compounds used in the treatment of primary amenorrhea. l Their
composition and usage was refined by numerous physicians into the oral and
injectable pregnancy tests of today.2-7 Most hormonal pregnancy tests are
composed of from 2.5mg to lOmg norethisterone acetate or 50mg ethisterone

(progesterones) with from .02 to .05mg ethinyl estradiol (estrogens).
ous companies around the world have produced and
names:

~arketed

Numer-

them under various

U.S.A. -- Squibb "Gestest" and Roussel "Pro-Duosterone"; Canada -- Will

"Duphaston", Barlowe and Cote IIEstro-Prodial
Schering A.G. and Knoll A.G. "Primodos oral

ll

and "Ethisterone"; West Germany

and J!Duogynon simplex"; Jordan
8 13
and U.A.R. -- Schering A.G. "Duogynon" and "Prirr:odos forte
- •
II

ll

•

•
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The teratogenic potential of any drug administered during pregnancy
has generally been thoroughly investigated by the

~2nufacturer

and the F.D.A.

Because of the use of hormonal pregnancy tests since the 1940·s, there had
been' much

clinical evidence of their efficacy with no reports of associated

congenital malformation.

Thus, hormonal pregnancy tests were considered safe

to the embryo with only the adverse effects on the user being investigated.
In 1961, the F.D.A. examined the clinical literature and passed hormonal
pregnancy tests as safe and effective for their intended purpose.

However,

since 1962 there has been mounting controversy regarding the teratogenic
potential of hormonal pregnancy tests.

Some researchers have found no terato-

genic connection while others have implicated thex in masculinization of the
female fetus, congenital neural tube defects (meningomyelocele and hydrocephalus),
congenital heart and VACTEL malformations,

spontan~ous

abortions, still births,

and congenital limb bud defects.

.

Review of the Literature
In 1962 Dubowitz 14 reported masculinization (non-adrenal female pseudohermaphordism) of a female infant whose mother had used hormonal pregnancy
tests.

Masculinization of the female fetus had long been known as an adverse
.
15-17
side effect of progesterone therapy for spontaneous abortlon.
However, this
was the first time a hormonal pregnancy test had been mentioned as a possible
18 20
cause. Then in 1967, Gal et al did a retrospective study of the mothers
of 100 babies born with spina bifida and hydrocephalus and compared them to
100 matched controls who bad delivered healthy

bab~es.

There was a signif-

icant difference in the number of hormonal pregnancy tests used by the
affected group as compared to the controls.

Thus, there vias a possible

.

association between congenital neural tube defects end hormonal pregnancy
tests.

Mitchell et al ,21-22 . in a study of heart disease in 56,109

- 3 -

birth suggested a possible correlationvtith hormonal therapy during
pregnancy and congenital transposition of great vessels (T.G.V.) of the
23
heart. Nora and Nora in a study of 10 patients with the congenital
anomaly kno\'/n by the acronym VI'"\CTEL (vetebral, anal, cardi ac, tracheal,
esophageal, limb defects) found 8 had been exposed to hormonal pregnancy
tests.

Also, a

retrospec~ive

study of 224 children born with con-

genital heart disease found that a significant number had received progesterone \A,i th estrogen duri ng the cri ti cal peri ad of cardi ogenesi s,
resulting in heart malformations, primarily transposition of the great

vessels.

In addition Levey et al~2 did a retrospective study of 76 cases

born \'-lith T.G.V. and concluded that hornlonal pregnancy tests or sex
hormones during pregnancy could be a predisposing factor in congenital
T.G.V. Nost recently, Janerick et al. 24 found that women \'Jho had
used oral contraceptives during pregnancy, hormonal supportive therapy,

.

or hormonal pregnancy tests had a higher' number of offspring

\~Jith

genital limb bud defects when compared to matched control mothers.

conLastly,

exogenous hormones have been implicated in increased spontaneous abortion
rate and increased still bi rth numbers. Brotherton and Craft 25 found
that out of 91 spontaneous abortions 7.6% had taken hornlonal pregnancy
tests.

The Royal College of General Practitioners· survey on the outcome
20
of pregnancy found a 10% abortion rate after "primodos ll administration.

Crombie et al~6 found a significant excess of hormone prescriptions in
a survey of still births.

Thus, retrospective studies have implicated

hormonal pregnancy tests as possible teratogens.

In contrast several researchers have found conflicting evidence to the
previous works. Dubm·titz and Srnithells 27 studied 189 mothers who had

-4-

used hormonal pregnancy tests and found that none of the female offspring
suffered from masculinization.

Laurence et al 28 in a study similar

to Gal's, compared 271 mothers of spina bifida children to 323 matched controls
and found no significant

between hormonal pregnancy tests and
29
In 1973 Oakley and Flynt did a retrospec-

as~ociat!on

children with neural tube defects.

tive study of Atlanta women who gave birth to malformed children.

Out of 433

women, 46 had taken hormonal pregnancy tests during the first trimester.
The proportion of women with positive histories of hormonal pregnancy tests
in each malformed group did not differ significantly from the proportion
observed in the total.

However, he concluded that there was an unusually

large number with esophageal atresia and that studies other than retrospective
ones could give more convincing evidence.

Lastly, in response to the findings

of Nora and Nora, David and O·Callaghan 30 tested the hypothesis that
hormonal pregnancy tests may cause esophageal atresia as part of VACTEL
syndrome.

They compared the sale of hormonal pregnancy tests and occurrence

of esophageal atresia over a 30 year

pel~iod

in South West England; but they

found no linear trend to indicate an association.

Thus, there has been con-

flicting research on hormonal pregnancy tests as teratogens.
Statement of Purpose

In 1973 the F.D.A. reviewed the clinical evidence since 1961 and the
National Academy of Science - National Research Council

D~Jg

Efficacy's

report and made the recommendation to withdra\1 approval of hormonal pregnancy
31
tests.
Thus, the F.D.A. reported in the Federal Register (1973) that
"Gestest" made by Squibb and other similar preparations CGuld be potentially
dangerous during pregnancy, and that proof of the drug's safety. was lacking.

-5-

In response to the reconlmendation) Squibb removed "Gestest" from their

products even though IIGestes t II \'/as 1is ted in the 1974 P.O. R. 32

However,

the final ruling had not been issued by the F.D.A. and legally hormonal
33
pregnancy tests could be produced and marketed in the U.S.
In 1975

Roussel, makers of "Pro-Duosterone

ll

,

~/ere

still sell ing their product; and

did not plan on removing it from the market.

34

Then in March 1975, the

F.D.A. made their final ruling and all hormonal pregnancy tests were dis36
continued in the U.S.
Of particular interest is that the initial F.D.A. approval in 1961
and the recommendation to withdrawal approval were based entirely on

clinical evidence supplied by the manufacturers and found in the literature
quoted.

As far as could be determined no animal studies had been used in

the evaluation of the product.

For example) previous to March 1975, the

medical director and vice-president of Roussel felt that the clinical
evidence was sufficient proof of safety, and that animal studies were

unnecessary.34 Squibb reported that "Gestest had been evaluated on only
clinical evidence. 32 Also, the F.D.A. stated that they had neither conll

ducted nor authorized any animal experimentation on the teratogenic potential
of this recently controversial drug.

33

The purpose of this study was to investigate the teratogenic potential

of oral hormonal pregnancy tests on pregnant Sprague Dawley rats.

The drug

was administered in both physiological and potentially teratogenic dosages
to the animals.

The mothers were sacrificed and the fetuses were examined

for various congenital anomalies.

Material and Methods
Animals:

Thirty-eight female Sprague-Dawley 21bino rats of 200-250

gram weights were divided into two groups.

T~e

of fifteen rats and the experimental group

control group consisted
of twenty-three rats.

cc~sis~ed

The control group was further divided into three subgroups of five animals
each and the experimental group into four
and one subgroup of three animals.

sub;ro~~s

of five animals each

The females were purchased as timed

pregnant rats from Charles Rivers Laboratories, Xassachusetts.

The rats

had been paired with male animals for fertilization from 5 P.M. to 8 A.M.
Pregnancy was indicated by a vaginal smear the follc'",ing morning, and a
positive smear was recorded as day zero of pregn~ncy.37 On the seventh
day of pregnancy the animals were shipped by tru:k to the University of

Connecticut Health Center.

Throughout the

experi~ental

period water and

a commercial diet were allowed ad libitum to all tbe animals.
Medication:

Pro-Duosterone·with the f01~~~la (ethisterone - 50.00mg

and ethinyl estradiol - O.03mg) was used as the
test in this experiment.

~odel

hormonal pregnancy

The ethisterone and ethinyl estradiol were

obtained as pure hormones from the Sigma Chemical Co~pany.38
hormones instead of prepared Pro-Duosterone

eli~inated any

Using pure

possibility

Qf not being able to obtain the drug should it be removed from the market.

The

b~sic

(0.122

~g)

animal dosages of ethisterone (204

~g)

and ethinyl estradiol

were calculated for a 225 gram rat at a level proportional by

weight to that consumed by a reference woman at 55 Kg.

The appropriate

dosages v/ere weighed on a Sartorius electronic balance type 2472.' The
drug (ethisterone and ethinyl estradiol) was

suspended in a solution of

•
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normal saline with 0.4% polysorbate 80.

The polysorbate 80

~las

added to

assure a uniform suspension, as ethisterone and ethinyl estradiol were not
water soluble and could possibly precipitate out before the appropriate
dosage was drawn off.

39

In addition) the hormones were passed through a

forty-four micron pharmaceutical seive prior to vleighing and suspension.
Reduction in particle size greatly reduced precipitation time once in
solution.

The hormone and saline mixture was prepared fresh at the be-

ginning of each three day administration period and kept refrigerated
at 38 F. to prevent any loss of potency or degradation of the drug. 40
The 5 experimental groups and 3 control groups received the following
dosages:

Group

I, controls -

Group

II, controls -

-Group III, controls -

nothing
0025 ml normal saline

.025 ml normal saline. 0.4% polysorbate 80
solation

Group

IV,

basic dosage (204

~g

ethisterone and .122

~g

ethinyl estradiol) in .025 ml normal saline
0.4% polysorbate 80 solution.
Group

V,

one-half the basic dosage (102
and e06l

~g

~g

ethisterone

ethinyl estradiol) in .025 ml normal

saline 0.4% polysorbate 80 solution.

Group VI,

two times the basic dosage (408
and .244 ~g

~g

ethisterone

ethinyl estradiol) in .025 ml normal

saline 0.4% polysorbate 80 solution.

•
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Group VII,

five times the basic dosage (1020
and .610

~g

saline 0.4%
Group VIII,

ethinyl estradiol) in .025 ml normal
30 solution.

polysorb~te

ethisterone and 1.240

~s

.025 ml normal

O.4~

sali~e

ethinyl estradiol) in
polysorbate 80 solution.

Each animal received .025 ml of suspension by

stomach tube three times per day at four hour intervals (9
5 P. M.) on the 11 th, 12th, and 13th day of pregnancy.
P.~1.) \vere

~g

twenty times the bcsic cQsage (4080

Timing of Administration:

(9 A.M. and 1

~g ethisteron~

at the standard dosages,

A.r~.

- 1 P.M. -

The fi rst

ho\".~ever,

t\aJO

doses

the third dose

(5 P.M.) was at double the concentration of hormones in .025 ml.

The double

concentration was necessary to duplicate the hUQan

pattern

of four times per day.

ac~inistration

The three day regimen also duplicated the human

treatment pattern of three consecutive days.41
days were selected because they eovered the

Th~

11th, 12th, and 13th

organoge~ic

that would include most of the human anomalies

repor~ed

following hormonal pregnancy tests.

d~~Uj

Thus, the

period in the rat
in the literature

Vias given during the

rat's critical period for the anomalies being investigated in this study.42-45
The 13th day in the rat is the critical period in development of the appendages
(digits and limbs), vertebra, skull, the ribs and the secondary palate.
The

12th and 13th days are

~lhen

and genital anomalies can occur.

final sexual differentiation occurs and anal
The three day period would also be critical

for development of the sense organs, fusion of facial processes, and spinal
anomalies (spina bifida, etc.) if they are to occur in the rat.
11th day is important for development of the tail and esophagus.

The

earlie~

-9-

Data Collected:

On the 19th day of pregnancy the animals were

sacrificed by ether anesthesia, the fetuses removed, and the following
data collected:

1.

Number of alive, dead, and resorbed fetuses in each group

2.

Weight and crown-rump length of each live fetus

3.

Sex of each live fetus.

The incidence of the following anomalies was
1.

2.
3.

4.
5.
6.
7.
8.
9.
10.
11.

12.
13.
14.
15.
16.

17.

Cleft lip
Cleft palate
Cleft lip and palate
Facial clefts
Anencephaly
Exencephalus
Hydrocephalus
Spina-bifida (meningocele)
Spina-bifida (n~elomeningocele)
Spina-bifida (nlyeloschisis)
Anopthalmia
Microphthalmia
External ear position and anomalies
Anal and genital anomalies
Hypoplastic tail
Joined twins
Limb and paw defects

In addition, fetuses
the Humason

46

recorded:

were

stained with alizarin red according to

method to allow examination of the skeletal system for

anomalies of:
1.
2.
3.
4.
5.

Ri bs

Vertebra
Limbs
Digits
Skull

Weight, Crown-rump length, and Sex determination:

Before

fetuses were blotted dry to remove excess fluids and blood.
then weighted on a Sartorius electronic scale type 1106.

weighing,

They were

Crovln-rump length

-,u-

was measured along the dorsal surface v/ith a flexible millimeter ruler
from the tip of the nose to the base of the tail.
the nlethod descri bed by Rugh.

42

Cro\'/n-runlp

Sex was determined by

measurements and sex

\~ere

determined by one investigator.
Skeletal examination:

All skeletal

ele~ents

were examined under a

dissecting microscope at approximately 7X by a single observer.

The

number of vertebrae and ribs vIas recorded; and the skeleton examined for
rudimentary and malformed ribs, limbs) digits, skull and facial bones.

RESULTS

For each treatment group.the following variables were determined:
1.

Mean nunlber of implantation sites

.2.

Mean number of live fetuses

3.

Percent of resorbed fetuses

4.

Percent of fetuses that were male

5.

Mean total fetal weight of each group (fig. 1)

6.

Mean individual fetal weight

7.

Mean individual fetal length.

One-way analysis of variance \yas performed for variables one to five

described above.

Statistical analysis found no significant

the .05 level for these variables (fig. 2).

diffel~ence

at

No discernible difference

between groups for variables six and seven were observed (fig. 3).
All fetuses were examined for the external ~alformations listed in the'
material and methods.

Infrequent minor anomalies

~:ere

detected in both

-11-

control and experimental groups; however, there was no tendency for an
increased frequency in the groups receiving the hormones.

No major external

anomalies such as: cleft palate, spina-bifida, hydrocephalus, etc. were ,
found in any fetuses (fig. 13,14,15).

Only one fetus 'in the group receiving

2X of. the bas i c dose had a defofmed 1eg (fi g. 4).

Minor anonlalies found included:
the medial dorsal surface, and one to

extended tail tips, dark spots on
t~/o

enlarged digits.

Extended tail

tips were defined as an extra soft tissue tip greater than lmm on the end
of the tail (fig. 5).

Numerous fetuses in all groups had extended tail tips

less than 1 mm; however, only two fetuses iri the 5X group had extended tail
tips.

Four fetuses with medial dorsal dark spots were found in the saline

and polysorbate groups (fig. 6).
'~ny,

of these specinlens.

from the saline,

~X~

Dissection showed no spinal defects in

Enlarged digits \-Jere found on three specilnens

and 5X groups (fig. 7).

.

In general, none of these

anomalies were related to experimental treatments, but instead represented
random developmental events.
Skeletal examination of the fetuses revealed vertebral variations,
supernunlerary ribs,

and malformed ribs.

No major deformations of the

limbs, paws, or skull were detected.
Variations in the

ve}~tebra

occurred in the center portion and were

classified as bilobed or split centra (fig. 8).
control and experimental groups.

They

\~ere

found in several

A chi square test for significance was

performed between the three control groups and the five experimental groups .
•

The three control groups were also compared to the 20X plus 5X groups, and
the 20X group.

The controls had a significantly lower incidence (.05 level)

of vertebral variations as compared to the

experi~2ntal

groups.

(fig. 9)

Supernunlerary or 14th rudimentary ribs \·:ere also found in several

controls and experimental groups.

The

small ossification centers to partially
they

\~ere

rudi~entarj

for~ed

ribs varied from

ribs (fig. 10).

found as unilateral and bilateral structures.

In addition,

Statistical analysis

revealed a significant increase at the .01 level _for rUdimentary ribs. in the
three experimental groups (1/2X to 2QX, 5X + 20X) and 20X).

Deformed ribs

appeared as wavy ribs (fig. 11) and appeared in groups: lX, 2X, and 5X.
However, the incidence was too small for statistical analysis (fig. 12)
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F

normal saline polysorbate

1/2X

X

# of

lX

2X

5X

20X

ratio

F
probe

12.2 11.6 13.6

12.0

1.06

.41

11.8

33.3

1.10

.39

43.3

33.3

1.29

.29

11 .4

11.4

11 .0

11 .2

12.3

3.5

9. 1

5.4

19.7

55.1

sites
%

resorbed

0

%

Male

48

41.8

46

45.3

10

11

10

10.6

26.8

25.8

26.7

28.9

X
# of live

46.6

9.8 11.6

12

8

.955

.48

.96

.48

fetuses

X

total
fetal
weight
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Deformed rear leg
2X Group

figure 4

No tail tip Polysorbate group

figure 5

Tail tip less than lmm - Normal group
figure 5

Tail tip greater than lmm - 5X group
figure 5

Dark spot on dorsal surface of fetus from polysorbate group
figure 6

Enlarged digits on fetus from group 2X
figure 7

Chi Square test of Control and Treatment Groups

Bilobular and Split Centra

Groups
I Controls - Groups
II
III

~X

Probability

to 20X

Controls - Groups 5X + 20X
Controls - Group 20X

P

= .0129

= .01
P = .02

P

Rudimentary Ribs
Groups
to 20X

P

= .00005

Controls - Groups 5X to 20X

P

= .000002

P

= .00001

I Controls
II

= Groups

Probabi 1i.t\!
-----:---

~X

III Controls - Group 20X

figure 9

figure 8

.figure 10

Split and bilobular centra .

Bilateral rudimentary 14th rib ..

Deformed ribs
figure 11

SKELETAL VARIATIONS IN OFFSPRlNG OF RATS

%Bi lobu far

% Rudimentary or Extra Ribs
Group

Unilateral - Bilateral

Total

or Spl it
Centra

Control

2.27

Sal i ne

5.45

3.64

9.09

20.

Polysorbate

3.57

10.71

14.29

25.

30.43

58.70

19.57

2.27

%Malformed
Ribs

6.82

1/2X

28.27 •

IX

12.50

5.

17.50

37.5

5.

2X

18.52

3.70

22.22

38.89

1.85

5X

24.44

2.22·

26.67

24.44

4.44

20X

33.33

8.33

41.67

20.83
•

figure

12

Fetuses

fro~

groups: Normal, Saline, Polysorbate,

lX, 2X, 5X

(upper left to rtght)
figure 13

Fetuses from groups: Normal, Saline, Polysorbate,
lX, 2X, 5X,

(upper left to right)
figure 13

Fetuses from groups:

Normal, Saline, Polysorbate and
(upper left to right)
figure 14

~X

Fetuses from groups:

IX, 2X, 5X and 20X (upper left to right)
figure 15
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DISCUSSION
Recently hormonal pregnancy tests have been implicated as potentially
teratogenic agents.

Retrospective studies have associated them with

masculinization of the female fetus, spinal defects, VACTEL syndrome, and
increased spontaneous abortion rate.
\'Ji thdrehl

In response, the F.D.A. in March 1975

approval of horn-Iona 1 pre9nancy tests because of thei r reported

teratogenic potential.

This study examined the effect of hormonal pregnancy

tests on the fetuses of albino rats.

The study stayed within physiologic

dose limits (1/2X to 20X) with no attempt to study the effect of

experime~tal

teratogenic dosages.
In general, the resul ts of the experilnent di d not support the contenti on

that hormonal pregnancy tests are potentially dangerous to rat fetal development.
This study found no increase in the per cent of resorbed fetuses in treatment
25
groups. This was in contrast to Brotherton and Craft and Crombie et a1 26 who

.

had reported increased spontaneous abortions and still births in humans with the
use of pregnancy test agents.

In this experiment, no genital anomalies were found and no increase in
percentage of male fetuses in treatment groups.

Masculinization could not be

clearly identified as no dissection of fetuses was performed in the present
The present study did not examine for esophageal atresia, anal anomalies,
T.G.V., and tracheal anomalies, as reported by Nora 2l , Levy22, and Mitchel1 23 .
study.

Skeletally there were significant increases in bilobular and split vertebra
centra and extra rudimentary ribs in the experimental group.

However, the

centra and .ribs may not be anomalies but variations of normal skeletal structures.
It is difficult to speculate how these variations would have expressed themselve~
in fully developed rats. Kuhns and Hormel1 47 reported that scoliosis and orthopedic problems in children are associated with variations and numerical alterations in the vertebra.

However, Kimmel and Wilson 48 indicated that extra

rudilnentary ribs and bilobular' centra should not be classified as abnorinal

and they may only be a sign of embriotoxicity.

Also, Bertilli and Donat;49

stated that the incidence of extra ribs is too high in nornlal rabbits to

be classified as an abnormality; however, it may be an indicator of drug

activity.
In conclusion, this study did not find conclusive evidence that oral
hormonal pregnancy tests at physiological doses are a treatcgenic agent

in white rats.

•
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